EP4164706A1 - Device and process for tissue-engineering and regenerative medicine - Google Patents
Device and process for tissue-engineering and regenerative medicineInfo
- Publication number
- EP4164706A1 EP4164706A1 EP20816241.2A EP20816241A EP4164706A1 EP 4164706 A1 EP4164706 A1 EP 4164706A1 EP 20816241 A EP20816241 A EP 20816241A EP 4164706 A1 EP4164706 A1 EP 4164706A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- preferentially
- cell
- microcarrier
- cells
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims abstract description 63
- 230000008569 process Effects 0.000 title claims abstract description 34
- 239000003814 drug Substances 0.000 title description 9
- 230000001172 regenerating effect Effects 0.000 title description 5
- 230000018044 dehydration Effects 0.000 claims abstract description 78
- 238000006297 dehydration reaction Methods 0.000 claims abstract description 78
- 238000012546 transfer Methods 0.000 claims abstract description 58
- 238000001727 in vivo Methods 0.000 claims abstract description 57
- 238000003501 co-culture Methods 0.000 claims abstract description 56
- 238000000338 in vitro Methods 0.000 claims abstract description 47
- 239000003190 viscoelastic substance Substances 0.000 claims abstract description 4
- 210000004027 cell Anatomy 0.000 claims description 277
- 238000007906 compression Methods 0.000 claims description 104
- 230000006835 compression Effects 0.000 claims description 104
- 239000000463 material Substances 0.000 claims description 69
- 238000002347 injection Methods 0.000 claims description 55
- 239000007924 injection Substances 0.000 claims description 55
- 239000012530 fluid Substances 0.000 claims description 39
- 239000000725 suspension Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 35
- 239000011148 porous material Substances 0.000 claims description 31
- 210000001519 tissue Anatomy 0.000 claims description 30
- 239000007943 implant Substances 0.000 claims description 23
- 239000004020 conductor Substances 0.000 claims description 16
- 238000002513 implantation Methods 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 16
- 230000001464 adherent effect Effects 0.000 claims description 15
- 230000036961 partial effect Effects 0.000 claims description 15
- 239000012528 membrane Substances 0.000 claims description 14
- 102000004127 Cytokines Human genes 0.000 claims description 12
- 108090000695 Cytokines Proteins 0.000 claims description 12
- 230000007423 decrease Effects 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 9
- 230000008859 change Effects 0.000 claims description 9
- 230000036571 hydration Effects 0.000 claims description 8
- 238000006703 hydration reaction Methods 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000001143 conditioned effect Effects 0.000 claims description 7
- 210000003722 extracellular fluid Anatomy 0.000 claims description 7
- 210000002220 organoid Anatomy 0.000 claims description 7
- 108090000623 proteins and genes Proteins 0.000 claims description 7
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 230000001965 increasing effect Effects 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 5
- 230000010261 cell growth Effects 0.000 claims description 5
- 239000002131 composite material Substances 0.000 claims description 5
- 230000000670 limiting effect Effects 0.000 claims description 5
- 230000001954 sterilising effect Effects 0.000 claims description 5
- 238000004659 sterilization and disinfection Methods 0.000 claims description 5
- 239000000853 adhesive Substances 0.000 claims description 4
- 230000001070 adhesive effect Effects 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims description 2
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims description 2
- 102000036693 Thrombopoietin Human genes 0.000 claims description 2
- 108010041111 Thrombopoietin Proteins 0.000 claims description 2
- 239000012298 atmosphere Substances 0.000 claims description 2
- 230000001939 inductive effect Effects 0.000 claims description 2
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 claims 1
- 102000003951 Erythropoietin Human genes 0.000 claims 1
- 108090000394 Erythropoietin Proteins 0.000 claims 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 claims 1
- 101150021185 FGF gene Proteins 0.000 claims 1
- 102100020880 Kit ligand Human genes 0.000 claims 1
- 101710177504 Kit ligand Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 239000006227 byproduct Substances 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- BNJOZDZCRHCODO-UHFFFAOYSA-N dimethyloxalylglycine Chemical compound COC(=O)CNC(=O)C(=O)OC BNJOZDZCRHCODO-UHFFFAOYSA-N 0.000 claims 1
- 229940105423 erythropoietin Drugs 0.000 claims 1
- 238000012239 gene modification Methods 0.000 claims 1
- 230000005017 genetic modification Effects 0.000 claims 1
- 235000013617 genetically modified food Nutrition 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 description 45
- 238000011068 loading method Methods 0.000 description 44
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 description 43
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 description 43
- 230000003394 haemopoietic effect Effects 0.000 description 43
- 239000012620 biological material Substances 0.000 description 35
- 238000010899 nucleation Methods 0.000 description 35
- 238000002474 experimental method Methods 0.000 description 34
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 34
- 238000001035 drying Methods 0.000 description 31
- 239000005090 green fluorescent protein Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 210000000130 stem cell Anatomy 0.000 description 27
- 210000002536 stromal cell Anatomy 0.000 description 24
- 210000001185 bone marrow Anatomy 0.000 description 20
- 230000011132 hemopoiesis Effects 0.000 description 20
- 241000699670 Mus sp. Species 0.000 description 19
- 239000004744 fabric Substances 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 19
- 108010035532 Collagen Proteins 0.000 description 18
- 102000008186 Collagen Human genes 0.000 description 18
- 229920001436 collagen Polymers 0.000 description 18
- 239000000017 hydrogel Substances 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 238000002054 transplantation Methods 0.000 description 16
- 230000035899 viability Effects 0.000 description 16
- 238000004140 cleaning Methods 0.000 description 15
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 14
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 14
- 210000000988 bone and bone Anatomy 0.000 description 14
- 239000002245 particle Substances 0.000 description 14
- 238000003556 assay Methods 0.000 description 13
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 12
- 238000011002 quantification Methods 0.000 description 12
- 239000002699 waste material Substances 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 11
- 239000001768 carboxy methyl cellulose Substances 0.000 description 11
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 11
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 11
- 230000001413 cellular effect Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 210000003491 skin Anatomy 0.000 description 10
- 238000007920 subcutaneous administration Methods 0.000 description 10
- 239000006285 cell suspension Substances 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 9
- 238000000684 flow cytometry Methods 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000003384 imaging method Methods 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 230000007704 transition Effects 0.000 description 9
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 8
- 210000001789 adipocyte Anatomy 0.000 description 8
- 238000003364 immunohistochemistry Methods 0.000 description 8
- 241001529936 Murinae Species 0.000 description 7
- 230000030833 cell death Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 238000012423 maintenance Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 229920005439 Perspex® Polymers 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 230000002706 hydrostatic effect Effects 0.000 description 6
- 238000002955 isolation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 6
- 229920000609 methyl cellulose Polymers 0.000 description 6
- 239000001923 methylcellulose Substances 0.000 description 6
- 239000004926 polymethyl methacrylate Substances 0.000 description 6
- 238000004062 sedimentation Methods 0.000 description 6
- 238000004114 suspension culture Methods 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 239000011324 bead Substances 0.000 description 5
- 230000006399 behavior Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000975 bioactive effect Effects 0.000 description 5
- 230000003592 biomimetic effect Effects 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000003636 conditioned culture medium Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000011065 in-situ storage Methods 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000011859 microparticle Substances 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- -1 poly(L-lactide) Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000010254 subcutaneous injection Methods 0.000 description 5
- 239000007929 subcutaneous injection Substances 0.000 description 5
- 230000003319 supportive effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 4
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 239000006143 cell culture medium Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000001332 colony forming effect Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000000495 cryogel Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000011067 equilibration Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000012417 linear regression Methods 0.000 description 4
- 210000003593 megakaryocyte Anatomy 0.000 description 4
- 239000012188 paraffin wax Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 3
- 108010022452 Collagen Type I Proteins 0.000 description 3
- 101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 3
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102100032399 Membrane-associated progesterone receptor component 1 Human genes 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000011072 cell harvest Methods 0.000 description 3
- 230000006727 cell loss Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 210000001612 chondrocyte Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 108010082117 matrigel Proteins 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 210000001178 neural stem cell Anatomy 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 108010047303 von Willebrand Factor Proteins 0.000 description 3
- 102100036537 von Willebrand factor Human genes 0.000 description 3
- 229960001134 von willebrand factor Drugs 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- 238000010146 3D printing Methods 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000906034 Orthops Species 0.000 description 2
- 102000001406 Perilipin Human genes 0.000 description 2
- 108060006002 Perilipin Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000011759 adipose tissue development Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003466 anti-cipated effect Effects 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 230000001427 coherent effect Effects 0.000 description 2
- 230000005757 colony formation Effects 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 238000010226 confocal imaging Methods 0.000 description 2
- 238000004624 confocal microscopy Methods 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000011194 good manufacturing practice Methods 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 238000011031 large-scale manufacturing process Methods 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 210000003098 myoblast Anatomy 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 238000000643 oven drying Methods 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000010412 perfusion Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 229920001432 poly(L-lactide) Polymers 0.000 description 2
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 210000002303 tibia Anatomy 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 240000001606 Adenanthera pavonina Species 0.000 description 1
- 235000011470 Adenanthera pavonina Nutrition 0.000 description 1
- 102000007325 Amelogenin Human genes 0.000 description 1
- 108010007570 Amelogenin Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010068051 Chimerism Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 101100440985 Danio rerio crad gene Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000899361 Homo sapiens Bone morphogenetic protein 7 Proteins 0.000 description 1
- 101000603882 Homo sapiens Nuclear receptor subfamily 1 group I member 3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 101150014058 MMP1 gene Proteins 0.000 description 1
- 244000070406 Malus silvestris Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100440987 Mus musculus Cracd gene Proteins 0.000 description 1
- 101100467905 Mus musculus Rdh16 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 229920001046 Nanocellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 101001012040 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) Immunomodulating metalloprotease Proteins 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 206010071051 Soft tissue mass Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010076089 accutase Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940105596 baytril Drugs 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000007175 bidirectional communication Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000008004 cell lysis buffer Substances 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 229910010293 ceramic material Inorganic materials 0.000 description 1
- 201000000760 cerebral cavernous malformation Diseases 0.000 description 1
- VYXSBFYARXAAKO-WTKGSRSZSA-N chembl402140 Chemical compound Cl.C1=2C=C(C)C(NCC)=CC=2OC2=C\C(=N/CC)C(C)=CC2=C1C1=CC=CC=C1C(=O)OCC VYXSBFYARXAAKO-WTKGSRSZSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 108700004333 collagenase 1 Proteins 0.000 description 1
- 239000012612 commercial material Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000013211 curve analysis Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 238000011013 endotoxin removal Methods 0.000 description 1
- 229960000740 enrofloxacin Drugs 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- SEACYXSIPDVVMV-UHFFFAOYSA-L eosin Y Chemical compound [Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C([O-])=C(Br)C=C21 SEACYXSIPDVVMV-UHFFFAOYSA-L 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000001497 fibrovascular Effects 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000007306 functionalization reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000003715 interstitial flow Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 238000007885 magnetic separation Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 238000007814 microscopic assay Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000012764 semi-quantitative analysis Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 210000001646 side-population cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 238000005476 soldering Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003153 stable transfection Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002381 testicular Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000013334 tissue model Methods 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
- C12N5/0075—General culture methods using substrates using microcarriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/432—Inhibitors, antagonists
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
Definitions
- This invention generally pertains to the tissue engineering and regenerative medicine fields.
- Biomaterials are increasingly used for in-vivo cell delivery (some examples: US2017136153A1, W02012149358 Al, W02013036875A1), where they often take the name of scaffolds(Garg et al., 2012). Besides offering adhesion sites for anchorage- dependent cells, they allow additional functionalities such as defined co-culture or pre vascularization (W02008008229A2). An interesting alternative is also to deliver cells and scaffolds separately. This is possible for mobile cells such as hematopoietic stem cells, when strong homing factors are known (W02017/136837A1). Scaffolds can further be composed of a variety of synthetic or natural polymers, but also decellularized extracellular matrix (for example, W02017/223529, W02016168752 Al).
- Injectable scaffolds for example preformed large scaffolds(Bencherif et al., 2012a), W02012149358 Al, but also other injectables, such as viscoelastic hydrogels (Nih et al., 2017) or cements (for example W02014160232A2) are of particular utility since they permit minimally invasive delivery.
- injectables such as viscoelastic hydrogels (Nih et al., 2017) or cements (for example W02014160232A2) are of particular utility since they permit minimally invasive delivery.
- For scaffold injection it is sometime necessary to dehydrate scaffolds; this is typically obtained by applying some sort of mechanical pressure during injection (Bencherif et al., 2012a) and/or partial dehydration before actual injection (Beduer et al., 2015a).
- Microcarriers are particles on the scale of tens of micrometers to the millimeter range. They are intended for the culture of adherent cells in suspension. Many different microcarriers are commercially available (the Cytodex, Cytopore and Cultisphere series being among the more renowned), and many fabrication methods and compositions established in the scientific and patent literature (example: EP1801122A1; defined shapes in W02014037862A1). Microcarrier-based cell culture is also a well-established art.
- microcarriers are large-scale production of cells or other biological such as antibodies or cells (example: hematopoietic stem cells, W00046349A1 and W02012127320A1); this can elegantly be combined with cell harvest by affinity to microcarriers (W02009/002456 A2).
- Microcarriers are also increasingly used to deliver cell therapy(example: US2015361395A1), since they can provide cells with adhesion during the transplantation process (Newland et al., 2015).
- the necessity for a defined transition with substantial volume reduction from a dilute suspension to a dense, transplantable injectable is particularly a problem for cells expanded to high numbers (typically, various stem cells such as embryonic stem cells, induced pluripotent stem cells, or endogenous stem cells such as hematopoietic stem cells and lymphoid progeny or neural stem cells), but also for postmitotic cells with a high-demand metabolism (for example, transient amplifying or progenitor populations, neurons, transport epithelia, cardiomyocytes or immune cells).
- various stem cells such as embryonic stem cells, induced pluripotent stem cells, or endogenous stem cells such as hematopoietic stem cells and lymphoid progeny or neural stem cells
- postmitotic cells with a high-demand metabolism for example, transient amplifying or progenitor populations, neurons, transport epithelia, cardiomyocytes or immune cells.
- microcarriers are cultured in large, dilute volumes to satisfy high metabolic needs arising from stem and progenitor cells, neurons, cardiomyocytes, transport epithelial cells or other highly active cells, and where in a second step injectable implants with high mechanical stability arising from partial microcarrier compression need to be produced.
- the application is to simultaneously transplant the cells and form mechanically stable local niche.
- the aspiration pressure applied to the interstitial fluid determines the final microcarrier density and indirectly the mechanical properties of the final implant.
- the dehydration rate as expressed by the fluid flow rate through relevant portions or all of the microcarrier material being compacted. As cells are sensitive to shear(Tanzeglock et al., 2009), this must be controlled if cell presence, integrity and if applicable cell interrelations are to be preserved.
- the compacted microcarriers need to remain with either directly a suitable syringe or a transfer device, rather than sticking to the fluid removal device, since otherwise it needs to be scraped of a membrane with concomitant risk of loss of cell viability, and generation of foreign particles.
- the present invention addresses these challenges.
- microcarriers lend themselves to the present invention, there are differences in their properties that make their ease of use or performance different. Scaffolds with hard, spherical particles yield relatively brittle pastes that are nearly unable to sustain shapes other than externally imposed ones; such an example is provided in the literature by partial rehydration for culture of metabolically relatively inactive cells (Fig. 8h in (Xia et al., 2017)), but can also be reached from suspension culture with the present invention by using for example cytodex microcarriers. In this case, the primary advantage of dehydration lies in the cell density.
- Softer, porous materials for example the commercial material cultisphere G or possibly newer non-porous (EP1801122A1) or porous gelatin carriers (EP3210634A1) make for more stable biomaterial pastes, most likely due to better shape-adaption and particle interlocking.
- the invention is particularly useful in conjunction with microcarriers exhibiting a plateau in compression such as the ones describes in W02017/029633; these are able to maintain their mechanical properties even for major volume changes; once adjusted these are resilient to loss of pore fluid by evaporation or dilution by addition of small to moderate amounts of liquid, for instance by contact with body fluids.
- Scaffolds have also been used to provide stromal functionality, for example by allowing implantation of mesenchymal stem cells for nerve repair (CN104491925B), or for co culture and co-transplantation of stem cells with stromal components, for instance to mimick a bone marrow environment for acute myeloid leukemia cancer stem cells, hematopoietic stem cells or other stem cells along with a mesenchymal stem cells cultured on the scaffold to provide stromal support (US2011/0207166A1).
- the present invention can also be advantageously used for such applications, provided the co-culture can be implemented on microcarriers suitable for this invention.
- a possible application of the present invention is the generation of an ectopic or new marrow niche for hematopoietic stem cells by means of a co-transplantation with stromal cells on microcarriers. It is indeed the basis of hematopoietic stem cell transplantation that hematopoietic stem cells are extraordinarly dependent on their niche for proliferation and maintenance. In fact, to guarantee successful engraftment, at least partial emptying of the hematopoietic niche of the recipient is at present necessary. Chemotherapy and whole-body irradiation are the major means to this end, although niche manipulation by injection of supplementary mesenchymal stem cells (W02016151476A1) together with the use of mobilizing agents such as GM-CSF are also being explored.
- An alternative means is to provide a local, possibly ectopic niche altogether (W02017136837A1, filled by separate transplantation of hematopoietic stem cells).
- the teachings of this invention can be used to create an injectable, yet coherent and shape-stable implant from a microcarrier-based co-culture of stromal cells (such as the OP9 line) and hematopoietic stem/progenitor cells after efficient in-vitro expansion under microcarrier culture conditions (cytokine-based, see for example W02017075389A1, or based solely on the action of the OP-9 or other stromal cells).
- the present inventors developed a process and device for direct in- vitro to in-vivo transfer of a living microcarrier culture by controlled dehydration into a viscoelastic material capable of cell-protection during delivery.
- One particular purpose of the present invention is that of providing a process and device for direct in-vitro to in- vivo transfer of living microcarrier co-cultures.
- the invention as described in here serves to compact a microcarrier culture or co-culture into an injectable implant with a paste-like consistency.
- the final implant remains injectable, but due to partial dehydration, has some mechanical strength, as evident for instance by rheometric G’ values in the range of lOPa to IMPa, more preferentially lOOPa to lOkP and most preferentially 500Pa to 5kPa.
- the partial dehydration system consists of a fluid drain capable of absorbing amounts at least equal, but typically by far (lOx or more) exceeding the amount of fluid to be absorbed from the microcarrier culture. It further is capable of separately, and stringently, regulate both final interstitial fluid pressure to be achieved (between 20 Pa and lOkPa, preferentially 50 Pa to lkPa, and even more preferentially between 100 Pa and 800 Pa below atmospheric pressure), and the maximum fluid flow rate experienced by microcarriers to subsequently be delivered in-vivo (or for in-vitro applications such as 3D printing) in the range between O.Olmm/s and lOcm/s, more preferentially between O.lmm/s and 5cm/s, and even more preferentially between 0.5mm/s and lOmm/s.
- the invention further comprises a transfer recipient.
- the dehydration process is initiated when the transfer device is loaded with the microcarrier culture, optionally through a filling column.
- the flow rate can be imposed by the dehydration system itself, or optionally, by a self-assembling dense plug of microcarrier material at the orifice of the transfer device in contact with the dehydration device. In this case, the dimensions of the orifice are key for the dehydration process.
- the desired final pressure which can optionally be monitored, for example by a pressure gauge or glass capillary in touch with the material being dehydrated
- the compacted, paste-like microcarrier culture is confined in the transfer device and can be manipulated or transported.
- the transfer device typically ensures connection to an injection syringe, or is itself an adapted syringe (with an air vent for piston insertion), and also ensures connection to the delivery tubing (typically, a catheter or blunt needle), through which the compacted, living microcarrier culture or co-culture is then delivered in-vivo. It is optionally possible to sub-sample some the compacted material to ensure appropriate composition and viability prior to injection.
- a “scaffold” is any three dimensional material having a framework architecture, for instance a support structure comprising hollow spaces within it.
- a scaffold is an artificial structure capable of supporting cell culture and/or three- dimensional tissue/organ formation in vivo, in vitro or ex vivo.
- a scaffold is also referred herewith as a “biomaterial” or “bioscaffold”.
- a scaffold can be considered the physical structure (including biodegradable and/or permanent materials) upon which or into which cells directly or indirectly associate or attach.
- a bioscaffold may allow or facilitate cell attachment and migration, delivers and retains cells and biochemical factors, enables diffusion of vital cell nutrients and expressed products, exerts certain mechanical and biological influences to modify the behaviour of the cell phase and so forth.
- a “polymeric material” is any material comprising polymers, large molecules (also known as macromolecules) composed of many repeated smaller units, or subunits, called monomers, tightly bonded together by covalent bonds.
- gel refers to a non-fluid colloidal network or polymer network that is expanded throughout its whole volume by a fluid.
- a gel is a solid three-dimensional network that spans the volume of a liquid medium and ensnares it through surface tension effects.
- the internal network structure may result from physical bonds (physical gels) or chemical bonds (chemical gels) such as covalent, ionic, hydrogen and/or Van der Waals bonds.
- a “microcarrier” is a particle on the scale of few micrometers up to millimeters, intended for the culture of adherent cells in suspension.
- Microcarriers can comprise or be substantially composed of polymeric materials such as plastic materials, biopolymers and/or ceramic materials.
- Many different microcarriers are commercially available (the Cytodex, Cytopore and Cultisphere series being among the more renowned), and many fabrication methods and compositions established in the scientific and patent literature (example: EP1801122A1). Microcarrier-based cell culture is also a well-established art.
- microcarriers are large-scale production of cells or other biological such as antibodies (example: hematopoietic stem cells, W00046349A1); this can elegantly be combined with cell harvest by affinity to microcarriers (W02009/002456 A2).
- Microcarriers are also increasingly used to deliver cell therapy (example: US2015361395A1), since they can provide cells with adhesion during the transplantation process (Newland et al., 2015).
- microcarriers according to the invention are substantially composed out of hydrogel.
- hydrogel refers to a gel in which the swelling agent is water.
- a hydrogel is a macromolecular polymer gel constructed of a network of cross-linked polymer chains. It is synthesized from hydrophilic monomers, sometimes found as a colloidal gel in which water is the dispersion medium.
- Hydrogels are highly absorbent (they can contain up to over 90% water) natural or synthetic polymeric networks. As a result of their characteristics, hydrogels develop typical firm yet elastic mechanical properties. Hydrogels have been used in biomedical applications, such as contact lenses and wound dressings.
- hydrogels are more biocompatible than hydrophobic elastomers and metals. This biocompatibility is largely due to the unique characteristics of hydrogels in that they are soft and contain water like the surrounding tissues and have relatively low frictional coefficients with respect to the surrounding tissues. Furthermore, hydrogels permit diffusion of aqueous compositions, and the solutes, there through, and have a high permeability to water and water- soluble substances, such as nutrients, metabolites and the like.
- hydrogel pore radius, morphology, or its permeability may change the hydrogel pore radius, morphology, or its permeability to different molecular weight proteins.
- volume or dimensions (length, width, and thickness) of a hydrogel can be selected based on the user’s needs, such as e.g. the region or environment into which the hydrogel is to be implanted in the frame of a surgical setting.
- the mechanical properties of the material can be tailored according to the application site by changing the hydrogel composition (molecular chain length, crosslinking, water content and the like).
- suitable materials constituting the microcarriers to be used in the frame of this invention include natural polymers, such as polysaccharides, co polymers of polysaccharides (cellulose, agarose, alginate, starch, chitosan and many others), polypeptides (silk, collagen, gelatin and many others), amelogenin or synthetic polymers such as polyurethanes, poly-olefins, polyethylene glycol (PEG), poly(glycolide) (PGA), poly(L-lactide) (PLA), carboxymethylcellulose (CMC) or poly(lactide-co-glycolide) (PLGA).
- natural polymers such as polysaccharides, co polymers of polysaccharides (cellulose, agarose, alginate, starch, chitosan and many others), polypeptides (silk, collagen, gelatin and many others), amelogenin or synthetic polymers such as polyurethanes, poly-olefins, polyethylene glycol (P
- the microcarrier may also comprise either at least one glycosaminoglycane or at least one proteoglycane, or a mixture of those two substances.
- the glycosaminoglycane may be for example a hyaluronic acid, chondroitinsulfate, dermatansulfate, heparansulfate, heparine or keratansulfate.
- the ability to use different materials is useful in different applications and adds a further degree of versatility to the device and methods described herein.
- the base material is not limiting as long as the other essential mechanical requirements are met, and the microcarriers can withstand a (partial) dehydration process.
- the degradation/resorption rate of the carrier upon in vivo application/implant in a host is mainly dependent on physico-chemical properties of the polymeric material of which it is composed of, as well as further factors such as crosslinking of the polymers, the polymer concentration, the site of implant into a host and the like.
- the degradation/resorption rate can be calibrated by adjusting said physico chemical parameters, such as for instance by polymer crosslinking (if present), the use of inhibitor molecules, by changing the polymer density, crystallinity and/or its molecular weight distribution, changing the materials’ porosity and so forth.
- the scaffold may be, at least in part and at least in some portion thereof, intrinsically biodegradable in vivo.
- Microcarriers can exist in different shapes and porosities.
- microcarriers according to the invention are highly porous and with an irregular shape.
- a preferred microcarrier in the frame of the invention comprises pores that are interconnected in order to create a continuous net of material that can act as a plausible physical support for elements such as cells or bioactive agents, while providing at the same time additional key features to the scaffold such as its softness, low resistance to interstitial flow, high compressibility, outstanding ability to regulate the capillary pressure to a constant level over a wide range of hydration states, easiness of cell/tissue invasion and so forth.
- the porosity of the material is preferably comprised between 50% and 99%, allowing for evacuation of liquid from the pores upon compression.
- Non-porous and/or regular shape microcarriers may be envisaged for use according to the invention.
- the pore size is typically comprised between lpm and 10mm, preferably between lpm and 5mm, more preferably between lpm and 2mm, even more preferably between 5pm and 500pm, obviously the size of the microcarrier itself being the upper limit of a pores size.
- This range of pore size is particularly convenient for a scaffold material for use in tissue engineering or regenerative medicine, since it is e.g. high enough to enable the growth of vessels through the porous material.
- the overall polymer content is comprised between 0.01% and 100% in mass of dry polymer material, preferably between 0.5% and 3%.
- liquid is removed therefrom and the hydration level decreases.
- Microcarriers are typically used in suspension state, wherein two main regimens exist: in a dilute regime, microcarriers are separated from each others, whereas in a dense regime, a contiguous network of neighboring microcarriers is formed.
- the progressive transition from a dilute regime to a dense regime is called “jamming transition”, and the microcarrier concentration associated to said jamming transition can be approximately found, as will be apparent to a person skilled in the art performing a sedimentation assay.
- the concentration at the jamming transition state can be considered as the full hydration state of a plurality of microcarriers (100% hydration).
- a “soft” material is any material that is either compressible, reversibly compressible, flexible, elastic or any combination thereof.
- the scaffold In order to be used in living subjects, moreover, the scaffold must also imperatively be a biocompatible and/or sterilisable material suitable for medical uses.
- a microcarrier and/or suspension according to the invention typically behaves, depending on the hydration state, as a viscoelastic material, particularly in the dense state of suspension as defined above (100% hydration or less). Depending on the shape, porosity, density and intrinsic material properties, an elastic response can be observed for low deformations whereas a viscous behavior is observed upon high deformations.
- the elastic regime is important for shape stability, whereas the viscous regime is considered important for injectability and shapeability of an implant.
- the scaffold material can be functionalized with additional elements such as for instance bioactive molecules.
- Said elements can be coated on or embedded within the obtained scaffold with any suitable means known in the art, and can provide additional functional properties to the material such as enhanced/reduced biodegradation, physical stabilization, biological activity and the like.
- a “bioactive molecule”, as well as “(bio)active compound” or “therapeutic agent”, is any active agent having an effect upon a living organism, tissue, or cell. The expression is used herein to refer to any compound or entity that alters, inhibits, activates, or otherwise affects biological or chemical events.
- bioactive compounds include, but are not limited to, a small molecule, a growth factor, a protein, a peptide, an enzyme, an antibody or any derivative thereof (such as e.g.
- multivalent antibodies multispecific antibodies, scFvs, bivalent or trivalent scFvs, triabodies, minibodies, nanobodies, diabodies etc.
- an antigen e.g., a nucleic acid sequence (e.g., DNA or RNA), a hormone, an anti inflammatory agent, an anti-viral agent, an anti-bacterial agent, a cytokine, an oncogene, a tumor suppressor, a transmembrane receptor, a protein receptor, a serum protein, an adhesion molecule, a lypidic molecule, a neurotransmitter, a morphogenetic protein, a differentiation factor, an analgesic, organic molecules, metal particles, radioactive agents, polysaccharides, a matrix protein, and any functional fragment or derivative of the above, as well as any combinations thereof.
- a functional fragment is herein meant any portion of an active agent able to exert its physiological/pharmacological activity.
- a functional fragment of an antibody could be an Fc region, an Fv region, a Fab/F(ab’)/F(ab’)2 region and so forth.
- the bioactive compounds can be added to the microcarrier material using any suitable method known in the art, such as surface absorption, physical immobilization, e.g., using a phase change to entrap the substance in the scaffold, and the like.
- a growth factor can be mixed with the microcarrier material composition.
- covalent coupling e.g., using alkylating or acylating agents, is used to provide a stable, long-term presentation of a bioactive substance on the microcarrier in a defined conformation.
- non-covalent adsorbtion can be used, for example electrostatic, hydrophobic, dipole-dipole, hydrogen bonding and the like.
- the microcarrier are basically cell-free, but they are later on seeded in vitro or in vivo with cells after their production with the intention to transplant cells in a tissue engineering/regenerative medicine approach.
- Cell seeding in its simplest implementation, involves placing the microcarriers in a cell suspension and letting the cells adhere and colonize the microcarrier.
- compressible microcarriers it is possible to greatly enhance the cell seeding process by partially dehydrating (compressing) the scaffold prior to addition of the cell suspension. In this case, the aspiration force created by the compressed microcarries tendency to expand draws the cell suspension into the microcarrier, and will seed cells deeply into the microcarrier.
- an external perfusion device to induce flow across the microcarrier and use this flow to efficiently seed cells.
- cell-adhesivity and/or porosity of the microcarrier plays a crucial role in organizing the cell seeding.
- Cells of a given type will only adhere in areas which are reachable for them by fluid flow, or, on a longer term, migration, and which allow for their attachment.
- a porous microcarrier it is possible to sterically entrap cells even when cells do not adhere to the microcarrier material per se.
- one cell type can mediate the attachment of another cell type which is not normally capable of adhesion to the microcarrier.
- Areas of very low pore size will act as a complete barrier for cell seeding by flow, be it by external perfusion or by intrinsically generated flow due to microcarrier expansion. This is the case of non-porous microcarriers, where only the microcarrier surface would be colonized by seeded cells.
- Different cell types or tissues fragments e.g., stem vs. differentiated, and/or with various phenotypes in terms of differentiation, activation, metabolic or functional state, are optionally co-resident in the microcarrier of the invention.
- the microcarriers should be chosen to be suitable for use with any cell type or tissue fragments that one may want to transplant.
- Such cells include but are not limited to, various stem cell populations (embryonic stem cells differentiated into various cell types), bone marrow or adipose tissue derived adult stem cells, mesenchymal stem cells, cardiac stem cells, pancreatic stem cells, neuronal cells, glial cells, spermatozoids and ovocytes, endothelial progenitor cells, outgrowth endothelial cells, dendritic cells, hematopoietic stem cells, neural stem cells, satellite cells, side population cells.
- Such cells may further include but are not limited to, differentiated cell populations including osteoprogenitors and osteoblasts, chondrocytes, keratinocytes for skin, intestinal epithelial cells, smooth muscle cells, cardiac muscle cells, epithelial cells, endothelial cells, urothelial cells, fibroblasts, myoblasts, chondroblasts, osteoclasts, hepatocytes, bile duct cells, pancreatic islet cells, thyroid, parathyroid, adrenal, hypothalamic, pituitary, ovarian, testicular, salivary gland cells, adipocytes and combinations thereof.
- differentiated cell populations including osteoprogenitors and osteoblasts, chondrocytes, keratinocytes for skin, intestinal epithelial cells, smooth muscle cells, cardiac muscle cells, epithelial cells, endothelial cells, urothelial cells, fibroblasts, myoblasts, chondroblasts, osteoclasts, hepatocytes,
- smooth muscle cells and endothelial cells may be employed for muscular or tubular scaffolds, e.g., scaffolds intended as vascular, esophageal, intestinal, rectal, or ureteral scaffolds; chondrocytes may be employed in cartilaginous scaffolds; cardiac muscle cells may be employed in heart scaffolds; hepatocytes and bile duct cells may be employed in liver scaffolds; myoblasts may be used in muscle regeneration; epithelial, endothelial, fibroblast, and nerve cells may be employed in scaffolds intended to function as replacements or enhancements for any of the wide variety of tissue types that contain these cells.
- scaffolds intended as vascular, esophageal, intestinal, rectal, or ureteral scaffolds e.g., chondrocytes may be employed in cartilaginous scaffolds
- cardiac muscle cells may be employed in heart scaffolds
- hepatocytes and bile duct cells may be employed in liver scaffolds
- myoblasts may be used in muscle
- microcarriers of the invention may comprise any cell population competent to participate in regeneration, replacement or repair of a target tissue or organ, particularly barely-reachable ones such as bone marrow, kidneys, brain, lungs or pancreas.
- a target tissue or organ particularly barely-reachable ones such as bone marrow, kidneys, brain, lungs or pancreas.
- Microcarriers according to the invention may be prepared or chosen so that the degradation time may be controlled by using a mixture of degradable components in proportions to achieve a desired degradation rate.
- the cells themselves aid in the degradation.
- scaffold compositions are sensitive to degradation by materials secreted by the cells themselves that are seeded within the scaffold.
- microcarriers according to the invention can be ideally transplanted on or close to a target tissue, introduced into or onto a bodily tissue/organ using a variety of methods and tools known in the art, preferably via minimally invasive surgical devices and procedures that envisage an injection step by using cannulas, syringe needles or catheters, preferably blunt ended catheters.
- the terms "patient” or “subject” refer to an animal, preferably to a mammal, even more preferably to a human, including adult and child. However, the terms can also refer to non-human animals, in particular mammals such as dogs, cats, horses, cows, pigs, sheeps, rodents and non-human primates, among others, that are in need of treatment. In some instances, a “subject” can be a plant.
- treatment generally refers to any act intended to ameliorate the health status of subjects such as an animal, particularly a mammal, more particularly a human, such as therapy, prevention, prophylaxis and retardation of the disease, and includes: (a) inhibiting the disease, i.e., arresting its development; or (b) relieving the disease, i.e., causing regression of the disease and/or its symptoms or conditions such as improvement or remediation of damage.
- such term refers to the amelioration or eradication of a disease or symptoms associated with a disease.
- this term refers to minimizing the spread or worsening of the disease resulting from the administration of one or more therapeutic agents to a subject with such a disease.
- prevention or “preventing” relates to hampering, blocking or avoid a disease from occurring in a subject which may be, for any reason, predisposed to the disease but has not yet been diagnosed as having it for example based on familial history, health status or age.
- dehydration device allowing to apply controlled pressure and flow rate during the dehydration procedure, with a transfer device that can, but does not necessarily have to be a syringe like device.
- the dehydration device or in the following also dehydration “box”, must be able to control final pressure and flow rate during the dehydration.
- an elementary implementation with a capillary conductor and a reservoir is given, but other solutions are also possible, for example with flow regulators driven by pressure regulators in an automated feedback loop.
- a separate transfer device for transfer of the compacted microcarrier culture to an injection device such as a syringe.
- the transfer device may however also be directly integrated with the syringe or other in-vivo delivery device, and if cell and material losses and possible foreign particle contamination can be accepted, manual transfer would also be possible.
- Example 1 Implementation of a dehydration device, transfer device and usage for injection
- This example provides a basic implementation of the dehydration device, transfer tip and filling column. It also describes the dehydration process used. It makes use a specific dehydration device, which has been designed to dehydrate a solution of microcarriers at an optimal interstitial pressure for injection (and thus optimal polymer concentration). It allows an efficient removal of the dead volume while guaranteeing a safe, reproducible and easy transition from the in vitro cell culture to the in vivo injection. The whole process is harmless for the cells to be transplanted. Dehydration is complete in few minutes and the compacted microcarriers are then ready to be injected in vivo. The whole system is autoclavable (all pieces are made from polypropylene plastic) and can be treated for endotoxin removal process (with concentrated sodium hydroxide) in order to prevent excessive inflammatory response from the host.
- endotoxin removal process with concentrated sodium hydroxide
- Fig. 1 shows the operating principle of the drying device.
- the sample is applied in a drying column.
- a pre-set aspiration pressure is generated by a lower level of fluid in the waste reservoir of the drying box, and is transmitted to the sample via a capillary conductor (cloth).
- the magnitude of the aspiration pressure is set by the level of fluid in the waste reservoir, and changes little during the dehydration process since the reservoir capacity by far exceeds the liquid volume to be removed.
- the direction of the fluid movement is determined by the relative magnitude of the elastic expansion force of the microcarrier sample in the drying column as compared to the imposed aspiration pressure. Therefore, after equilibration, the aspiration pressure determines the fluid content of the microcarrier sample regardless of the initial fluid content.
- the fluid flow rate is determined by the difference of expansion pressure and hydrostatic under-pressure, but also by the total flow resistance.
- the primary source of flow resistance is the microcarrier material near the tip of the transfer column.
- Fig. 2 provides an overview over the process flow used to obtain an injectable from microcarrier cultures.
- the starting material in this embodiment is a dilute suspension of carboxymethylcellulose microcarriers (CCM, synthesis given in Example 2) colonized with the cells of interest (typically, but by no means necessarily, a co-culture of HSPC and OP-9 feeder cells, Fig. 2A), but the principle is the same with any microcarrier culture (cells and carriers).
- CCM carboxymethylcellulose microcarriers
- Fig. 2A a co-culture of HSPC and OP-9 feeder cells
- This dilute suspension is transferred to the dehydration column, which consists itself of two parts, namely the loading column and the transfer tip (Fig. 2B). Excess fluid is drained into the waste reservoir by the dehydration box, until equilibrium with the aspiration pressure set by fluid level in the waste repertoire is reached (Fig. 2B).
- the microcarriers form a paste-like material, contained in the transfer tip. This material holds in place, such that the loading column can be removed.
- the transfer tip is then attached to a syringe and equipped with an injection catheter (Fig. 2C).
- the microcarrier-based injectable can now be transferred in vivo (Fig. 2D).
- the drying is composed of 2 separate parts: i) a drying column and ii) a drying box (Fig. 1).
- the drying column handles the microcarriers, while the drying box is designed to apply a precisely known aspiration pressure and to remove excess pore fluid until equilibrium with the aspiration pressure is reached.
- the drying columns are themselves composed of 2 parts: the loading column and the transfer tip (as shown in Fig. 2).
- the loading column is adapted to receive an important amount of volume, typically the content of a 6-well plate well.
- the transfer tip is plugged at the bottom part of the loading column. It acts as an adaptor for both the column and the needle.
- the design of the transfer tip must be such that it maintains the compacted microcarriers when lifting the transfer tip off the capillary conductor (or filter membrane).
- the transfer tip is designed to be conical (cone opening angles between 0° and 180°, preferentially 1° to 90°, more preferentially between 2° and 45°, even more preferentially between 3° and 30°, and most preferentially between 5° and 20°).
- conical cone opening angles between 0° and 180°, preferentially 1° to 90°, more preferentially between 2° and 45°, even more preferentially between 3° and 30°, and most preferentially between 5° and 20°.
- Alternative measures to ensure maintenance of the compacted material can be taken, such as temporary placement of a filter membrane to be removed horizontally with minimal force on the microcarrier.
- the tip opening is also a crucial element for regulation of the fluid flow rate.
- the tip opening diameter is in between about 20% of the fully expanded microcarrier size to a maximum of about 5cm, more preferentially between 50% of the average fully expanded microcarrier size and 1cm, and even more preferentially between 100% of the average fully expanded microcarrier size and 0.5cm.
- the box is composed of a drying platform and a waste reservoir.
- the capillary conductor (contacting cloth) ensures the connection between these two compartments.
- the capillary conductor is optionally also active as a filter to maintain the particles in the transfer tip during dehydration.
- its pore size show be adapted to exclude particles from entering the capillary conductor; depending on particle elasticity, it is sufficient to have a pore size smaller than the microcarrier size, or it is necessary to have it much smaller.
- a filter membrane is imposed between capillary conductor and transfer tip; in this case, the minimal requirement on the capillary conductor is merely not to lose all of its pore water at the desired set pressure to maintain sufficient hydrolic conductivity for the dehydration process.
- the filter membrane in that case should have a pore size at most on the size scale of the microcarriers, preferably much smaller (including down to nanometric sizes such as standard 0.22 micrometers or 0.45 micrometer filter membranes).
- the waste reservoir is a Falcon tube into which a whole at a given height has been drilled to ensure a constant level of saline buffer whatever the exact amount of excess medium in the CCM solution.
- the excess of liquid will indeed leak out of the tube by the hole performed at a specific height defined by the experimental needs. Indeed, polymer concentration may vary from one application to another.
- a drying box with a preset height of hole at 2cm equivalent to about 200 Pa aspiration pressure), which we find to produce a CCM concentrate suitable for a subcutaneous injection while preserving cell viability.
- Fig. 3 shows the technical dimensions of a drying column, which consists of two mandatory pieces: the loading column and the transfer tip. Optionally, it can be closed with a cap on its top.
- Fig. 5 shows the relationship between the dry weight polymer concentration of the biomaterial and the aspiration pressure as set by the height difference Ah between the shelf of the pipet box and the lower edge of the pressure regulator hole.
- Ah the height difference between the shelf of the pipet box and the lower edge of the pressure regulator hole.
- the binder fluid in some applications, and in particular to maintain the fluid associated with the microcarriers during extrusion or injection, it is advantageous to render the binder fluid more viscous, for example by adding methylcellulose, carboxymethylcellulose, agarose, starch, polyethylene glycol or any of a large number of cell compatible vicosing agents.
- methylcellulose, carboxymethylcellulose, agarose, starch, polyethylene glycol or any of a large number of cell compatible vicosing agents Typically, one wishes to increase the viscosity of the interstitial fluid by a factor of 2x to lOOO’OOOx in such applications. For the lower viscosities, addition to cell culture medium may be sufficient.
- the aim of this example is to estimate the admissible linear compression in sample microcarrier system for co-culture of hematopoietic stem cells and the stromal OP-9 line.
- Compressible carboxymethylcellulose scaffolds in accordance with W02017/029633 are produced by cryogel bulk scaffold synthesis.
- a reaction mix consisting of 13.56mg/mL carboxymethylcellulose (AQUALON CMC 7LF PH, 90.5 KDa, DS: 0.84) and 0.486mg/mL adipic acid dihydrazide, buffered with 6.3mg/mL PIPES neutralized to pH 6.7 by 1.2mg/mL NaOH was prepared and filtered through a 0.22um filter (Stericup).
- the mix was frozen at -20°C in 30mL syringes. After 48h of ciyo-incubation, the syringes are thawed.
- the scaffolds thus obtained are then fragmented to irregular, compressible microcarriers by extrusion through a 22G catheter. This yields a suspension of microscaffolds suitable for use as microcarriers. These microcarriers are then extensively washed, and autoclaved for sterilization.
- the surface of the sterile microcarriers is covalently modified with collagen type 1 (from bovine skin, Sigma, C4243), producing collagen- coated carboxymethylcellulose microcarriers (CCM).
- collagen type 1 from bovine skin, Sigma, C4243
- CCM carboxymethylcellulose microcarriers
- the collagen-coated carboxymethylcellulose microscaffolds (CCM) were rinsed twice with D1 water in order to remove the excess of non-adsorbed proteins.
- covalent crosslinking of the collagen was performed by immersing the CCMs in a solution containing EDC (1 mg/ml) and MES buffer (pH 4.5, 100 mM) in D1 water for 10 minutes.
- EDC EDC
- MES buffer pH 4.5, 100 mM
- Example 3 Microcarrier culture and viability
- the aim of this example is then to evaluate stability of the collagen-coated carboxymethylcellulose microscaffolds CCM as described in Example 2, seeded with cocultures of murine stromal OP9 and hematopoietic stem and progenitor cells (murine hematopoietic stem and progenitor cells or HSPC, obtained by sorting bone marrow extract for ckit + , lin-, Sca-1 + “KLS”). Seeded at an initial OP9:KLS ratio of 100:1, the CCMs were cultivated for 3 months to achieve steady-state cellular composition prior to mechanical and cellular stability testing against controlled uniaxial compression. This data allows to follow the fate of the co-cultures on the CCMs during controlled compression, and thus to estimate the allowable compression during injection.
- collagen-coated CCMs were seeded using 75,000 OP9 (GFP) and 7,500 KLS (DsRed) per mg of dry scaffold weight. After initial incubation to allow for cell adherence, the scaffolds were distributed in ultra-low adhesion plates; a 6-well plate (2mg of dry scaffold/well) and a 24 well plate (0.5mg of dry scaffold per well). Culture was performed by adding first 3mL respectively 0.5mL of conditioned medium, and then another 3mL respectively 0.5mL at day 7, followed by half-media changes every week for 3 months. We took care to avoid aspiration of the CCMs by holding the plate in a slanted position for about 30s prior to medium aspiration. This allows the CCMs to sediment and be protected from aspiration. The procedure however is expected to remove a sizeable fraction of the cellular descendance generated by in-vitro hematopoiesis at each medium change.
- This chamber consisted of a laser cut Perspex sheet in the shape of a microscope slide (i.e. 75mm x 25mm), with a rectangular central observation area (30mm x 12.5mm), closed with a floor consisting of a glued coverslide (Fig. 1A).
- a laser-cut cleaning cloth made from polypropylene and cellulose (Migros, Switzerland) into the central area (Fig. 6A).
- the cleaning cloth matched the dimensions of the central observation area (nominally 30mm x 12.5mm, de facto about 0.25mm smaller at each edge due to the finite laser spot size), but in addition we cut a circular hole at its center (8mm nominal diameter, real diameter estimated about 8.5mm).
- This circular hole serves as sample concentrator, but also as holder for uniaxial compression with a 8mm circular chuck (Fig. 6B). After compression, the samples can be observed by confocal microscope (Fig. 6C).
- cell culture medium i.e. 50/50 mix of conditioned and fresh medium as described in the main text
- 50mM HEPES 50mM HEPES
- Fig. 7 shows the detailed setup used for uniaxial sample compression.
- the machine is calibrated for force gain by the standard calibration routine in the Texture Exponent user interface.
- a microscope coverslide identical to the one used for compression chamber fabrication is then placed onto the sample stage of the TextureAnalyzer XTPlus machine, and chuck height calibration is carried out. In this way, the zero-height is defined at upper surface of the coverslide.
- the compression chamber with previously loaded sample is placed under the chuck, giving rise to the compression setup as shown in Fig. 7.
- the chuck is then lowered to establish contact with the sample, taking care to avoid air bubbles.
- the chuck is moved vertically until zero net force is detected; this is done by a built-in routine for this purpose available in the TextureExponent program.
- the observation chambers were kept closed with a second coverslide during transport and microscopic observation; between experiments, medium was replenished if necessary by placing a drop of medium (50/50 mix of conditioned and fresh medium with 50mM HEPES as described above) such as to keep the clefts between cleaning cloth and Perspex sheet fully filled, indicating minimal capillary pressure. This was necessary since opening and closing by sliding the closing coverslide (Fig. 1C) removed a small amount of medium sticking to the coverslide.
- Fig. 9 shows confocal images illustrating the effect of various degress of uniaxial compression (0%, 75%, 100%) on the co-cultures of OP9 (green) and KLS+ descendance (red).
- Fig. 9A and Fig. 9B show that qualitatively, mere contact with the chuck (Fig. 9A) and even transient uniaxial compression by 75% of the original sample height (Fig. 9B) has only minor effects on the co-cultures, whereas 100% compression kills a large fraction of the cells.
- Fig. 10 shows a quantitative analysis of the percentage of dead cells compared to the estimated total number of cells. While no significant difference can be detected between the material simply loaded into the observation chamber (“Control: Loading” in Fig. 10) and contact with the compression chuck but no actual compression. We detect a significant increase in the dead cell fraction after the 75% uniaxial compression, although the co-culture still remain largely intact (raise of the dead cell fraction from 7% to 13%). Theoretically complete compression on the other hand leads to the immediate death of more than 50% of the cells.
- composition of the viable cell fraction during compression is a composition of the viable cell fraction during compression
- Fig. 11 shows the results regarding the composition of the remaining viable cell fraction.
- This fraction is composed of distinct green (GFP+, OP9) and red (DsRed+, KLS and descendance) fluorescent cells.
- Control: Loading We find a slight, but statistically significant decrease of the DsRed+ fraction after the chuck zero-force equilibration procedure (from 53% to 45% on average, P-value of 0.04 associated with equilibiration vs. initial loading in linear regression with both the culture and equilibration vs. initial loading as explanatory variables, Bonferroni correction for a total of three tests against the 0% compression condition). Compression by itself then has little influence on the average DsRed+ fraction, although the variability increases especially for the 100% compression, where cells are killed in entire image areas.
- the strain e in turn is obtained by relating the compressive chuck displacement Ah to the sample height ho :
- Eq. 1 and eq. 2 correspond to the so-called « engineering » (Moosbrugger, 2002) stress and strain, since the original sample dimensions are used in their calculation(Moosbrugger, 2002).
- Fig. 12 shows the stress-strain diagrams for the four compression experiments: to 75%, and then again from original sample height to 100% compression, for the two samples prepared (one from the 6-well culture, one from the 24- well culture).
- the Young modulus is defined as the change of stress per unit of change of strain: da eq. 4 de
- Fig. 13 outlines the Young moduli as estimated from eq. 4 plotted against the polymer concentration as estimated by eq. 3. Over a wide range, a 3 rd power law is observed for both samples, in agreement with a similar law reported for bulk ciyogel scaffolds. (Beduer et al., 2015a)
- the polymer concentrations shown on the x-axis of Fig. 13 should be considered indicative: It is quite difficult to determine the exact polymer concentration reached when loading the polymer chamber. For the small volumes used for the compression measurement, the mere act of transferring to a scale causes pore fluid to be lost. We performed two experiments to define the upper and lower bounds of the polymer concentration after loading.
- the actual polymer concentration is expected to between the upper and lower bounds thus determined. As a reasonable estimate, we indicate the range midpoint and the upper and lower bounds as extremes, and therefore assume the loading concentration to be 8+/- 2mg/mL.
- Fig. 13 indicates that the implants have Young moduli in the lower kPa range (1.2+/-0. 6kPa). Also, there is well-respected 3 rd power law for the dependency of Young modulus on the polymer concentration throughout a large part of the polymer concentration range throughout the compression experiments.
- the 3 rd power reflects the mechanics of a porous elastic structure(Beduer et al., 2015a) where increasing compression leads to loss of pore fluid without major change of the mechanical structure.
- HSPC hematopoietic stem and progenitor cells
- Flow cytometry and hematopoietic colony forming assays demonstrate the stromal supportive capacity for in vitro hematopoiesis in the absence of exogenous cytokines.
- Our approach provides a minimalistic, scalable, biomimetic in vitro model of hematopoiesis in a microcarrier format that preserves the HSPC progenitor function, while being injectable in-vivo without disrupting the cell-cell interactions established in vitro.
- microcarriers of example 2 We used here the microcarriers of example 2.
- Collagen CCMs surface coating We coated here the microcarriers of example 2.
- OP9s mesenchymal stromal cell line
- the total bone marrow cell pellet was resuspended in 3mL volume and loaded into a magnetic separation cell Sorter (AutoMACS, Miltenyi) to remove all lineage positive (Lin+) cells in suspension.
- the resulting cells were then blocked for 15 minutes on ice (5pg/ml hlgG; I4506-10MG, Sigma Aldrich), and finally stained for one hour on ice with lineage Streptavidin-PO (1/200), as a conjugate to label any remaining Lin+ cells, as well as c-Kit PE-Cy7 (1/200), Sca-1 APC (1/100).
- the cell suspension was run through a FACS system (Aria Fusion) and the resulting Lin-, c-Kit+, and Sca-1+ (KLS) cells were sorted into Iscove’s Modified Dulbecco’s Medium (IMDM) + Glutamax, 25mM HEPES (31980022, Life Technologies) supplemented with 10% FBS and 1% P/S.
- IMDM Modified Dulbecco’s Medium
- 25mM HEPES 25mM HEPES (31980022, Life Technologies) supplemented with 10% FBS and 1% P/S.
- 2-3 adult male DsRed+ mice were euthanized to collect approximately 200,000 KLS+ cells in suspension for each experiment.
- FACS cells were kept on ice for approximately 1-2 hours until co-seeding with OP9s on the scaffold.
- All cells for co-seeding experiments were cultured in 50% fresh basal media (1MDM + Glutamax 25mM HEPES, 10% FBS, 1% P/S) and 50% conditioned 1MDM media (CM).
- Conditioned media was obtained by culturing confluent GFP+ OP9s with IMDM media for two days (48 hours), filtering the conditioned medium, and freezing the media for no longer than two months at -20°C. After HSPCs and OP9s were collected in suspension and counted, cells were kept on ice for maximum 1 hour.
- 3D co-seeding Collagen-coated microscaffolds (CCMs, 13.5 mg/ml in PBS) were dried using a cell strainer in a SteriCup filtration system (C3240), using an autoclave cloth to transmit the capillary pressure. Once dried, the globule of CCMs was transferred to a 6- well ultra-low adhesion plate (Corning, CLS347) using the tip of a 2 mL stereological pipette. For each condition, the two cell types (HSPCs, OP9s) were combined, spun down, and re-suspended in a minimal amount of media (approximately 100 pL in total).
- HSPCs were seeded at the previously established co-seeding ratios, 1:10 “high” (12,000 HSPCs per well) and 1:100 “low” (1,200 HSPCs per well). If limited by HSPC cell number, the 2D condition was performed with only the low seeding density. Cells were fed at D7, complementary to the 3D culture timeline, with 3mL added and no media removed, then cultured at 37°C and 5% CO2 for 12 days in total. Co-seeding experiments were repeated in at least two separate experiments, with technical triplicates within each experiment.
- Compression testing was performed to assess the limit of compression compatible with cell survival in example 3.
- Cells were collected for each condition (high/low; 2D/3D) in three fractions: cells in suspension, cells adherent to the CCMs, and any cells adherent to the ultra-low adhesion plates.
- media was collected in a 50 mL falcon tube, and cells were washed and collected twice with serum-free media.
- CCMs adherent fraction cells were detached via enzymatic digestion as follows. CCMs were transferred to 24 well plates with a 1000 um pipette tip and 1 mL of collagenase 1 (17100-017, ThermoFisher Scientific) 0.04% was added per well of CCMs for 25 minutes at 37°C and 5% CO2.
- CFU methylcellulose colony forming unit
- each CFU plate was read using a StemVision instrument (Stem Cell Technologies), and total colonies were assessed automatically (StemVision proprietary software) and verified manually on the acquired high-resolution whole-plate images according to colony number, size, and cell distribution (Mcniece et al., 1990).
- Example 3 After 14 days of in vitro culture, seeded-CCMs in suspension were collected from the well plate and poured into the column of the drying device (Example 1) allowing for the CCMs to settle down into the reservoir and reach the desired interstitial aspiration pressure (ca. 200Pa) and therefore polymer concentration (26 +/- 3 mg/ml, Example 3). This condenses the CCMs into a paste-like material with a Young modulus of 1.2+/-0.6 kPa [Example 3 ), which we find sufficient to sustain a 3D architecture in vivo. Sterile syringes were used to aspirate 0.1 ml of coated scaffold without cells, followed by 0.1 ml of air to ensure separation between them. The reservoir with the sedimented cultured scaffold (50 pL) was connected to a lmL syringe and a 20G flexible catheter (BD Biosciences 381703) was plugged in the other end.
- BD Biosciences 381703 20G flexible catheter
- NSG mice were chosen for the experiments as OP9 stromal cells are derived from a mixed genetic background and therefore purely syngeneic transplantation was not possible.
- anesthesia was induced in NSG mice with 4% isoflurane USP- PPC (Animalcare Ltd).
- An ophthalmic liquid gel (Viscotears, Alcon) was used to protect the eyes and local isoflurane was reduced to 2%.
- Mice were placed on a heating pad to keep the temperature constant during intervention, and the back of each mouse was shaved at the area of the injections. Betadine (Mundipharma Medical Company) was spread onto the shaved regions to disinfect the skin.
- a small orifice was created in the disinfected skin using a 18G needle and the 20G catheter (Tro-Vensite i.v. canula, Troge, Hamburg), connected to the loaded syringe, which was gently inserted subcutaneously about 2 cm from the pierced skin.
- the 20G catheter Troge, Hamburg
- two separate injections of 50 pL each were performed subcutaneously on either side of the spine. No sutures were required.
- the mice were placed back in the cage grouped per condition. The entire preparation of the scaffolds and all the injections were performed under the hood to ensure sterility throughout the whole procedure. Each injection, from start to finish, lasted less than 20 minutes per mouse.
- Animals were treated with antibiotics in drinking water consisting of 30 mg of Enrofloxacin (300 pL of Baytril 10% ad us. vet, 100 mg/mL, Bayer) and 5 mg of Amoxicillin (100 pL of Amoxi-Mepha 200mg/4mL, Mepha Pharma AG) as well as 500 mg of Paracetamol (Dafalgan®) in a total of 250 mL sterile water for the entire duration of the study and replaced every 7 days. Animals were monitored daily by the researchers, and after two weeks, they were monitored daily by animal care services.
- NSG immunodeficientmice were euthanized 12 weeks post-injections through inhalation of CO2 (6 minutes). The back was shaved gently to better localize the two implants. The samples were harvested in each mouse being careful to keep some subcutaneous tissue around to study the integration of the scaffolds within the normal tissue. Samples were then fixed for 24 hours in 4% paraformaldehyde at 4°C (10 mL PFA in 15 mL Falcon tube), washed three times with PBS, and embedded in paraffin.
- Tissues were fixed in paraformaldehyde (PFA), submitted for stepwise dehydration and embedded in paraffin blocks for sectioning at 3-4 pm thickness with a rotary microtome (RM, Leica microsystems) .
- PFA paraformaldehyde
- RM rotary microtome
- sections were mounted on glass slides (Superfrost+ slides, Menzel glaser). Paraffin sections were stained with Hematoxylin and eosine (H&E) using the Tissue-Tek Prisma automate (Sakura) and permanently mounted using the Tissue-Tek glas G2-coverslipper (Sakura) to assess morphology.
- H&E Hematoxylin and eosine
- Detection of rabbit anti-GFP (Abeam, ab6673, diluted 1:400), rabbit anti- Dsred (MBL, PM005, diluted 1:500), rat anti-CD31 (clone SZ31, Dianova, DIA-310-M, diluted 1:50), rabbit anti-vWF (Abeam, ab9378, diluted 1:100) or rabbit anti-Perilipin (Abeam, ab3526, diluted 1:200) was performed manually. After quenching with 3% H202 in PBS lx for 10 minutes, a heat pretreatment using 0.1M Tri-Na citrate pH6 was applied at 60°C in a water bath overnight. Primary antibodies were incubated overnight at 4°C.
- Co-seeded CCMs were kept in 3D culture for 12 days in vitro. At days 1, 4, 7, and 11, a small volume of suspended CCMs were removed and transferred to a deep cavity glass microscope slide (produced in lab for imaging, see Example 3, Fig. 6). Within an hour after transferring CCMs to the imaging chamber, they were imaged at varying magnifications (20X for imaging quantification; 63X for cell morphology) using a Zeiss LSM 700 Inverted Confocal Microscope. As the cells were endogenously labeled for GFP (OP9s) and DsRed (HSPCs), serial imaging was conducted at each time point without significant cellular manipulation.
- GFP OP9s
- HSPCs DsRed
- Images used for quantification were composed of a 25-z-stacked, volume- rendered image. To analyze the data, each fluorescent channel was separated and the compiled volume-rendered image was used. Each image/channel was analyzed using Fiji/lmageJ’s threshold tool, with the resulting quantified fluorescent areas converted to cell numbers by using the mean area per cell, as established by manual identification of a subset of the cells. For each 3D experiment, a total of eight independent CCMs were analyzed from two experiments to plot the relative cell proliferation over time.
- RESULTS The study aimed to provide a microcarrier co-culture system for convenient and minimally invasive injection of a tissue-like living biomaterial, without disrupting cellular viability and multi-cellular interactions during the injection procedure.
- stromal OP9s and HSPCs on porous CCM microscaffolds (Fig. 14A).
- the system self-organized such that the OP9 stroma lined the scaffolds coated with collagen 1 to support the HSPC subpopulations (Fig. 14B), and allowed for in vitro studies in diluted microcarrier suspension cultures.
- the intact co-cultured CCMs, together with their cellular payload were dehydrated by a custom dehydration device (Fig. 14C, Example 1) and delivered in vivo by subcutaneous syringe- injection (Fig. 14D).
- our starting biomaterials are highly elastic and porous microscaffolds consisting of crosslinked carboxymethylcellulose.
- a 3D view based on confocal reconstruction after staining with rhodamine 6G is provided in Fig. 14E.
- the microscaffolds are designed to be reversibly compressible. This allows for facile exchange of the pore fluid by arbitrary sequences of dehydration and rehydration.
- To obtain the collagen-coated microscaffolds CCM we made use of such cycles to efficiently and covalently functionalize the microscaffolds with collagen type 1 to provide native stromal cell adhesion motives.
- Collagen-coated, mesenchymal stromal cell-seeded scaffolds promote hematopoietic cell proliferation over time
- confocal imaging showed effective spreading of OP9 stromal cells on the CCM scaffolds and attachment of the co-seeded HSPCs to the OP9s, with continuous proliferation of hematopoietic cells within the scaffold over 11 days in culture (Fig. 15A).
- the stromal cells are essential, since at 24 hours HSPCs failed to adhere to the CCMs in the absence of the OP9 cells (Fig. 15B, Fig. 15C).
- Fig. 15D HSPC nestling within OP9 stromal cells
- Fig. 15E colony formation within the matrix after 3-4 days of culture
- HSPCs and their progeny as identified by the DsRed + GFP- population, consisted nearly exclusively of CD45+ cells, as expected for all cells of the hematopoietic lineage derived from bone marrow HSPCs (Fig. 16B) (Weissman and Shizuru, 2008). These cells, which expressed no lineage markers in the cell surface at seeding (Linage- is part of the KLS definition), consisted at day 12 on a mixture of lineage negative and lineage positive cells (Fig. 16B). Acquisition of major lineage markers thus revealed hematopoietic differentiation within the CCM coculture.
- CFU assays which quantify the number of oligopotent progenitors able to form functional hematopoietic clonal colonies after a 7-10 day culture in semi-solid, cytokine-rich media.
- Fig. 16F shows an example of a CFU assay at 7 days.
- the number of relative colonies is significantly higher in the “low” (1:100) seeding condition (2D: 1093.86 ⁇ 567.88, 3D: 764.69 ⁇ 306.84) as compared to the “high” (1:10) condition (2D: 408.34 ⁇ 126.32, 3D: 369.42 ⁇ 99.46), suggestive of either nutrient competition or a negative paracrine regulation by differentiating hematopoietic cells at higher CFU seeding densities. Compared to controls obtained by direct plating of fresh KLS cells without culture prior to the methylcellulose assay, we observed a maintenance, or minor expansion, of the functional HSPC compartment.
- cytokines commonly used for in vitro HSPC expansion (e.g. thrombopoietin, stem cell factor, or Fms-related tyrosine kinase 3 ligand, (Costa et al., 2018)).
- the aim here was indeed to provide a minimalistic system enabling further screening without interference from exogeneous cytokines.
- Compressible porous scaffolds have previously demonstrated promise in providing an injectable solution to traditional cell-based tissue engineering techniques (Beduer etal., 2015b; Bencherif et al., 2012b).
- Fig. 17A-D shows the workflow for transitioning from a microcarrier-like suspension culture to a transplantable co-culture biomaterial.
- the CCMs After a predefined time of in vitro culture as a dilute suspension (Fig. 17A), the CCMs are collected and dehydrated to a controlled level by a device specifically designed for that purpose (Fig. 17B, and detailed information in Example 1).
- the device applies a pre-set hydrostatic pressure to the CCMs by means of a capillary conductor.
- the hydrostatic pressure sustained by the biomaterial constituted by the CCM is strongly linked to its concentration, this ensures constant material consistency compatible with regards to injection and hematopoietic niche reconstitution in vivo.
- Example 1 we set a hydrostatic pressure difference of 0.2kPa, equivalent to a fluid level difference of about 2cm, to concentrate the co-culture biomaterial to 26 +/- 3 mg/mL (Example 1). At this concentration, the material remains easily injectable and matches the kPa range for the vascular part of the bone marrow niche (Bello et al., 2018), as detailed in Example 1.
- the transfer tip is fitted onto a syringe, and assembled with a catheter (Fig. 17C) for subcutaneous injection (Fig. 17D).
- Fig. 17C a catheter for subcutaneous injection
- Fig. 17E we assessed whether the procedure of partial dehydration and passage through the catheter during the injection would be harmful to the cells.
- hematoxylin and eosin standard histological staining revealed intact scaffold particles (Fig. 18A, D and G).
- the scaffold was host to diverse cell types.
- Immunohistochemistry (IHC) against GFP revealed strong persistence of confluent OP9 stroma across the scaffolds shown by the large areas stained in brown (Fig. 18E and H). Such staining was absent from the initially cell-free CCM implants (Fig. 18B), providing evidence for the specificity of the anti-GFP staining.
- anti-DsRed IHC revealed a positive signal only for scaffolds loaded with both GFP+ OP9s and DsRed+ HSPCs (Fig.
- murine HSPC/OP9-seeded CCM scaffolds can be implanted in NSG mice to produce highly vascularized structures which retain donor stroma and contain locally active hematopoiesis as well as interspersed adipocytes, features reminiscent of adult marrow (Weiss, 2008).
- CCMs are easily fabricated with standard equipment (freezer, autoclave for sterilization, laminar flow hood for coating under sterile condition), such that production is easily scalable at affordable costand compatible with Good Manufacturing Practice (GMP) production.
- standard equipment freezer, autoclave for sterilization, laminar flow hood for coating under sterile condition
- the CCMs feature covalently bound collagen I (Beduer et al., 2018; Serex et al., 2018). Indeed, among a series of extracellular matrix molecules, collagen type I has been shown to provide the highest proliferation levels with KLS cells (Choi and Harley, 2017). Further, contrary to Matrigel used for generation of hematopoietic ossicles (Bello et al., 2018; Hughes et al., 2010; Reinisch et al., 2017), collagen I is a single protein of defined composition that is amenable to clinical use (Lecarpentier et al., 2018; Salvade et al., 2007).
- OP9 cells have been shown to direct pluripotentstem cells towards the hematopoietic fate, and also have an ability to maintain engraftable hematopoietic stem cells in in vitro 2D co-cultures systems for up to 2 weeks in the absence of additional cytokines (Naveiras, 2009).
- the combination of OP9 cells and CCMs was found not only to enable the baseline culture of HSPCs over 12 days in culture, but also to provide for easy and effective implantation of the hematopoietic scaffolds in vivo for a follow-up of 12 weeks in NSG mice.
- the HSPC compartment as measured by the CFU counts in the 2D versus 3D cultures (Fig. 16G), is essentially unaffected by this lower output of total hematopoiesis.
- the 3D cultures are effectively concentrated in a much smaller volume with higher local cytokine levels (Rodling et al., 2017)
- our results point towards differential regulation of hematopoiesis in our configuration leading to HSPC enrichment, which may be ascribed to the difference balance of the hypothesized “vascular” versus “endosteal” niches (Leisten etal., 2012; Sanchez-Aguilera and Mendez- Ferrer, 2017).
- tissue engineered BM has provided a first indicator of supporting subcutaneous, extramedullary hematopoiesis in healthy adult murine tissue without simultaneous ossification. We observe some induction of adipogenesis, pointing towards bidirectional communication between the niche and the hematopoietic compartment.
- cytodex3 dehydrated material The performance of the cytodex3 dehydrated material is slightly less good (Fig. 20): As for the CCM material, the dehydration device performs perfectly, but a significant amount of cells (OP9) are lost during injection. This is truly cell loss, as the amount of cell death on the cytodex beads does not increase (Fig. 20). Even so, the amount of cells conserved as measured by the GFP area confluence remains significantly above 0, demonstrating that the general method of dehydration and injection can clearly still be used with cytodex 3 microcarriers.
- Example 6 Cell survival in-vivo in different materials
- Fig. 21 compares relative in-vivo transfer efficiency for different materials. From Fig. 20, we anticipated some cell loss for microcarriers that are not specifically adapted for the purpose and therefore seeded lOx more cells than on the CCM carriers (Example 2).
- Fig. 21 The preliminary results shown in Fig. 21 indicate that there is about an order of magnitude of cell loss for the cultisphere G, cytodex 3 and also a non-porous CCM analog. Nevertheless, sufficient cells survive to deliver a living implant, indicating applicability of the method to different microcarriers even though it is evident that engineering appropriate properties into the microcarriers themselves increases the efficiency of the process.
- OP9 show long-term engraftment in NSG mice (3 months; see also Fig. 18).
- This example provides characterization of the dehydration box, transfer tip and drying column as described in Example 1, for dehydration of CCM microcarriers as synthesized in Example 2.
- These data show that for a wide range of set target aspiration pressures (indicated as cm H20 where 1cm H20 is about 98 Pa), the volumetric flow rate is independent on the applied pressure (Fig. 22A).
- cm H20 where 1cm H20 is about 98 Pa
- Fig. 22A For low microcarrier concentration as typical for dilute suspension culture, there is also relatively little variation of the flow rate with varying polymer concentration, although the flow rate will decrease at higher polymer concentration when approaching the equilibrium.
- Example 8 Layered compacted microcarrier culture.
- FIG. AB shows the layered compacted microcarrier culture.
- HFF human foreskin fibroblasts
- Example 9 Integrity of the microcarrier system after exogenous or endogenous reloading
- This example provides evidence for the integrity of the microcarrier system, once injected, to accept reloading at a second timepoint, whether by reinjection or by colonization of local resident cells that acquire the capacity to colonize the microcarrier through the presence of the stromal layer.
- a total of 0.4 ml of the partially dehydrated CCM microcarrier suspension was delivered subcutaneously as described extensively in examples 3 and 4.
- a suspension of 40 microliters of cell-emulating low diffusion carbon microparticles was carefully injected (Fig. 25A).
- Fig 25B the microcarrier system preserved its geometry after receiving the secondary graft.
- Fig 25c shows how the cell-emulating microparticles delivered at a second timepoint could distribute through the previously injected microcarrier while preserving the microscopic architecture.
- Fig. 25D-E 30-50 microliters of the partially dehydrated CCM microcarrier suspension were injected intra-bone, through the murine tibial plate, into the bone marrow cavity.
- Fig. 25 D-E show at low and high magnification the microcarrier suspension integrating into the bone marrow hematopoietic tissue and thus the potential of the so-delivered microcarrier suspension to incorporate the functional progenitor populations in situ.
- Luhmes organoids were commercially obtained from Neurix SA, Geneva, Switzerland. They were layered below microcarriers functionalized with Matrigel and then subjected to partial dehydration and culture at a negative pressure of -0.9kPa on a diffusive membrane, while providing fresh medium at a flow rate of 100 micrometers/s on the other side of the membrane. These culture conditions were maintained for 7 days, before fixing the samples with 4% PFA, and processing for paraffine embedding. The samples were stained for Bill tubulin and DAP1. The results of the experiment (Fig. 24 C) show nearly complete integration of the microcarriers into the organoids (80-90% integrated area compared to original size of organoid) with maintenance of organoid viability.
- Fig. 1 Schematic representation of the hydrostatic pressure applied by the device.
- a capillary conductor drives the pressure applied by the level in the waste reservoir of the drying box to the sample in the drying column.
- the pressure can easily be adapted by changing the level of liquid in the waste reservoir.
- Fig. 2 Overview of the transition from in vitro culture to in vivo injection.
- A) In vitro co culture of OP9 (stromal cells) and HSPC (KLS) inside our collagen-coated CCM. The biomaterial is used as a microcarrier in a diluted form.
- B and C) Concentration the diluted CCM by the drying device. The protocol is detailed below.
- Fig. 3 Technical details of the drying column.
- the drying column consists of a loading column and a transfer tip.
- the transfer tip is reversible attached to the loading column by pressing.
- the loading column can be closed by a cap.
- Fig. 4 Technical layout of the drying box.
- the drying box a customized pipet tip box: a waste reservoir with a lateral hole for pressure regulation is inserted into tip shelf, and a capillary conductor in the form of specifically cut wiping cloth is laid out onto the plateau. An extended part of the capillary conductor extends into the reservoir to transmit the aspiration pressure set by the position of the pressure regulator hole.
- the pipet box also serves as a containment for the excess liquid leaving the waste reservoir by the pressure regulator hole.
- Fig. 5 Relation between aspiration pressure and the dry weight polymer content of the CCM biomaterial (uncoated precursor). The aspiration pressure is expressed by the height difference between the pressure regulator hole and the plateau of the drying box (Ah in Fig. 4).
- Fig. 6. Observation chamber adapted for uniaxial compression.
- sample in the sample area can be compressed uniaxially. Excess liquid is taken up by the cleaning cloth. C) After compression, the sample can be observed by confocal microscopy. For this purpose, the chamber can be closed reversibly by a second microscope coverslide to limit evaporation.
- Fig. 7 Uniaxial sample compression. A sample is loaded into the circular sample area (Fig. 6, here in cross-section), defined within the cleaning cloth. The compression chamber is then placed onto the sample stage of a mechanical testing machine (TextureAnalyzer XTPlus) and then compressed by uniaxial movement of the chuck. Excess liquid squeezed out from the pore space during compression is drained by the cleaning cloth.
- a mechanical testing machine TextureAnalyzer XTPlus
- Fig. 8 Z-projection (maximum intensity) of a confocal stack of a co-culture of OP9 and KLS on CCMs at 3 months. Hoechst 328 was used to stain for nuclei of dead cells.
- Fig. 9 Z-projection (maximum intensity) of a confocal stack of co-cultures of OP9 and KLS on CCMs after uniaxial compression by 0% (A), 75% (B) and 100% (C) of the original sample height. Hoechst 328 was used to stain for nuclei of dead cells.
- Fig. 10 Quantification of cell death at different levels of compression.
- the loading control corresponds to transfer to the compression chamber only, without contact with the chuck; this is closest to the actual culture conditions.
- 0% compression indicates contact and zero-force equilibration with the chuck of the uniaxial testing machine (TextureAnalyzer XTPlus), but no actual sample compression.
- 75% indicates a decrease in sample height by 75%, whereas 100% indicates theoretical total compression.
- the fraction of dead cells is the fraction of predominantly blue cells after Hoechst 328 staining, as compared to the total number of cells (predominantly blue + predominantly red + predominantly green).
- the compression experiments were repeated twice, once with starting material from a 6-well-plate culture, once with starting material from a 24-well- plate culture.
- Fig. 11 Quantification of the composition of the remaining viable cell fraction.
- the DsRed+ fraction is the fraction of red fluorescent cells compared to green + red fluorescent cells; conditions are as for Fig. 10, and evaluation based on the same images.
- Statistical significance was evaluated pairwise by comparison to the 0% compression condition. For this, linear regression with the experiment and condition (0% compression vs. loading control, 75% compression, 100% compression) as explanatory variables and the DsRed+ fraction as the outcome was used, and the P- value associated with the condition evaluated for significance.
- Fig. 12. Uniaxial compression Stress-Strain diagram. Four measurements were done: to 75% compression, and then to 100% compression on a total of two samples (one reconstituted from each culture condition).
- Fig. 13 Young modulus as a function of polymer concentration. Eq. 4 is used for the estimation of the Young modulus from the data shown in Fig. 12; eq. 3 is used to estimate the polymer concentration from the strain shown in Fig. 12.
- the triangles labelled “0% compression” and “75% compression” outline the estimated polymer concentrations at which the viability quantifications for the 0% compression and 75% compression conditions were done; the grey triangle labeled “Implantation” indicates the estimated concentration of the biomaterial for the in-vivo implantation experiments (26mg/mL, see Example 1).
- Fig. 14 Transplantable bone marrow niche.
- stromal cells O9 are combined with hematopoietic stem and progenitor cells (HSPC, selected from bone marrow as lineage-, ckit+, Sca-1+ cells); the resulting cell mix is loaded onto collagen- coated carboxymethylcellulose microparticles (CCMs).
- CCMs carboxymethylcellulose microparticles
- CCMs For in-vivo implantation, the cell-loaded CCMs are slowly dehydrated to form a paste-like implantable living biomaterial. Both dehydration speed and final dehydration level are carefully controlled.
- E Structure of a CCM.
- F CCM (stained by cell impermeant Hoechst dye) along with green fluorescent stroma and red fluorescent hematopoietic compartment.
- G Assignment of the different areas as scaffold, HSPCs and lineage-committed progenitors, and stromal cells (OP-9). Confocal images are linearly contrast adjusted.
- Fig. 15 In-vitro co-culture of OP9 MSCs and HSPCs on CCMs.
- Qualitative observations from imaging demonstrate large-scale structural outline of the seeded CCMs.
- C OP9 stroma
- FIG. 16 3D culture outcome compared to 2D controls via flow cytometry and colony forming assays.
- the stem and progenitor fraction was finally obtained as cKit+ cells within the Lin-CD45+ population (C).
- C Lin-CD45+ population
- D Total CD45+ expansion through flow cytometry, identifying 2D and 3D cell proliferation for both the 1:10 and 1:100 seeding densities.
- E Total CD45+, cKit+ cell expansion for the same conditions, demonstrating closer similarities between the four conditions.
- F Total colony count after 7 days in methylcellulose medium, after harvesting total cells from the CCMs (after 12 days of in vitro culture).
- Fig. 17 Implantation of CCM-based co-cultures.
- A After seeding, the co-cultures can be cultured in-vitro as classical microcarrier suspension cultures.
- B To prepare an implant, the material is partially dehydrated to by equilibrating to a predefined hydrostatic pressure level (DR), typically on the order of 0.2kPa (ca. 2cm water column). This is done in a specifically designed transfer tip.
- DR hydrostatic pressure level
- the transfer tip is attached to a syringe and an implantation catheter (to avoid accidental intravascular injection).
- D The co-culture biomaterial is injected subcutaneously.
- E In vitro assessment of injection viability as quantified through GFP+ OP9 MSC and HSPC cell confluence before, immediately after, and 24 hours after injection (biomaterial seeded 1:100 HSPC - OP9, used at day 1 in vitro).
- F Macroscopic external view of the implant in the subcutaneous dermal tissue 12-weeks post-implantation.
- G Visibly vascularized scaffold after sacrifice, seen from the inside of the skin flap.
- Fig. 18 Histology and cellular composition of implanted scaffolds. Unseeded CCMs (A-C), as well as CCMs cultured with OP9 (D-F) or with 1:10 “high” co- cultures of OP9 and KLS cells (G-I) were implanted into the dorsal skin of NSG mice, and retrieved after sacrifice at 12 weeks. Samples were processed for hematoxylin/eosin (H&E) staining (A, D, G), as well as immunohistochemistry with primary antibodies directed against GFP (B, E, H, marker for OP9 cells) and DsRed (C, F, I, marker of HSPC and progeny).
- H&E hematoxylin/eosin staining
- B, E, H marker for OP9 cells
- DsRed C, F, I, marker of HSPC and progeny
- Fig. 19 Immunohistochemistry of scaffolds transplanted in vivo. Unseeded scaffolds (A- C) and HSPC/OP9-seeded scaffolds (D-I) were recovered 12 weeks after subcutaneous transplant. Paraffin sections of scaffolds were stained with anti-vWF (A, D, G, arrows indicate megakaryocytes), anti-Perilipin (B, E, H), and anti- CD31 (C, F, I), and antibodies. Scale bars are lOOpm. CD31+ vessels were quantified (J), error bars indicate mean HSD (p ⁇ 0.003).
- Fig. 21 In-vivo cell transfer efficiency; Various microcarriers were seeded with OP9 cells (GFP+). For the CCM (porous, synthesis described in Example 2), 3*106 cells/mg were seeded, for the others 30*106 cells/mg to compensate for anticipated losses. Relative cell transfer efficiency was quantified from histological cuts as the number of nuclei associated with GFP+ cells.
- Fig. 22 Dehydration rate measured as volumetric flow rate in CCM as function of target pressure and initial polymer concentration.
- Fig. 23 Estimated linear fluid velocity at the neck of the transfer tip (maximum expected linear average fluid velocity, 4mm neck diameter). From the data of Fig. 22.
- Figure 24 A) Non-layered, compacted microcarrier culture of a non-adhesive cell type (BC1, human neural stem cells). B) Layered compacted microcarrier culture of first adhesive cell type (human foreskin fibroblast) and secondary adhesive cell type (BC1). C) Microcarrier-tissue composite (LUHMES organoids). (1) shows the diffusive membrane while (2) shows the microcarrier-tissue composite.
- BC1 non-adhesive cell type
- first adhesive cell type human foreskin fibroblast
- BC1 secondary adhesive cell type
- M1 Microcarrier-tissue composite
- LHMES organoids Microcarrier-tissue composite
- Figure 25 A-C) In situ re-loading of subcutaneously injected microcarrier system.
- A) Intact skin after re-loading of the microcarrier system with cell-emulating low diffusion carbon microparticles.
- C) A magnification of the explanted microcarrier system showing the microscale distribution of the re-injected microparticles (black).
- D-E Intra-bone injection of the microcarrier system.
- D) Fractured tibial plate at the site of injection (1) and the delivered microcarrier system (2) into the marrow space (3).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Dispersion Chemistry (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19020673 | 2019-12-04 | ||
PCT/EP2020/084615 WO2021110908A1 (en) | 2019-12-04 | 2020-12-04 | Device and process for tissue-engineering and regenerative medicine |
Publications (1)
Publication Number | Publication Date |
---|---|
EP4164706A1 true EP4164706A1 (en) | 2023-04-19 |
Family
ID=68807973
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20816241.2A Pending EP4164706A1 (en) | 2019-12-04 | 2020-12-04 | Device and process for tissue-engineering and regenerative medicine |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP4164706A1 (en) |
WO (1) | WO2021110908A1 (en) |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4438015A1 (en) | 1994-10-25 | 1996-05-02 | Boehringer Mannheim Gmbh | Bio-materials for treating skin wounds, e.g. burns, senile ulcers and diabetic wounds |
ATE452181T1 (en) | 1999-02-04 | 2010-01-15 | Pluristem Ltd | METHOD AND DEVICE FOR MAINTAINING AND EXPANSING HEMATOPOIETIC STEM CELLS AND/OR PROCURSOR CELLS |
KR20020043557A (en) | 1999-08-13 | 2002-06-10 | 바이오폼 인크. | Tissue Augmentation Material and Methods |
US20050048036A1 (en) | 2001-12-07 | 2005-03-03 | Hedrick Marc H. | Methods of using regenerative cells in the treatment of inherited and acquired disorders of the bone, bone marrow, liver, and other tissues |
EP1660629A4 (en) * | 2003-07-17 | 2015-04-08 | Global Cell Solutions Llc | Automated cell culture system and process |
WO2006014158A1 (en) | 2004-07-01 | 2006-02-09 | Macropore Biosurgery Inc. | Treating disorders by administering regenerative cells. |
EP1801122A1 (en) | 2005-12-23 | 2007-06-27 | FUJIFILM Manufacturing Europe B.V. | Recombinant gelatin particles for cell adhesion |
TW200817019A (en) | 2006-07-10 | 2008-04-16 | Univ Columbia | De novo formation and regeneration of vascularized tissue from tissue progenitor cells and vascular progenitor cells |
US20100291219A1 (en) | 2007-06-21 | 2010-11-18 | Massachusetts Institute Of Technology | Methods and compositions relating to progenitor cells |
US20110207166A1 (en) | 2009-11-06 | 2011-08-25 | Sarah Rivkah Vaiselbuh | Human bone marrow microenvironments and uses thereof |
KR101903339B1 (en) | 2011-03-22 | 2018-10-01 | 플루리스템 리미티드 | Methods for treating radiation or chemical injury |
ES2685327T3 (en) | 2011-04-28 | 2018-10-08 | President And Fellows Of Harvard College | Injectable preformed macroscopic three-dimensional frames for minimally invasive administration |
WO2013036875A1 (en) | 2011-09-07 | 2013-03-14 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
PT106225B (en) | 2012-03-23 | 2017-11-03 | Inst Superior Técnico | EXCESSIVE EXPANSION PROCESS OF BIREMETICAL STEM CELLS |
CN105385596A (en) | 2012-09-06 | 2016-03-09 | 普拉里斯坦有限公司 | Devices and methods for culture of cells |
EP2948541B1 (en) | 2013-01-28 | 2019-09-18 | Rutgers, The State University of New Jersey | Growth matrices for stem cell propagation in vitro and in tissue regeneration |
CN105263438A (en) | 2013-03-14 | 2016-01-20 | 托莱多大学 | Injectable biodegradable bone matrix for multiple myeloma lesion augmentation and osteoporosis |
JP6346672B2 (en) | 2014-10-22 | 2018-06-20 | 富士フイルム株式会社 | Microcarrier adjustment method, microcarrier and its application |
CN104491925B (en) | 2014-12-17 | 2016-04-06 | 浙江大学 | A kind of gel stent implant system of combined with mesenchymal stem cells and application thereof |
IL294058A (en) | 2015-03-23 | 2022-08-01 | Pluristem Ltd | Use of adherent stromal cells for enhancing hematopoiesis in a subject in need thereof |
WO2016168752A1 (en) | 2015-04-17 | 2016-10-20 | The Regents Of The University Of California | Decellularized human amniotic membrane for cell delivery, cell culture and inflammation prevention |
GB201514788D0 (en) | 2015-08-20 | 2015-10-07 | Ecole Polytech | Malleable scaffold material and uses thereof |
TW202344686A (en) | 2015-10-30 | 2023-11-16 | 美國加利福尼亞大學董事會 | Methods of generating t-cells from stem cells and immunotherapeutic methods using the t-cells |
US10532128B2 (en) | 2015-11-18 | 2020-01-14 | Viera Bioscience, Inc. | Implantable cellular therapy device for treatment of graft versus host disease and tolerance induction |
JP7138864B2 (en) | 2016-02-06 | 2022-09-20 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Recapitulation of the hematopoietic niche to reconstitute immunity |
WO2017223529A1 (en) | 2016-06-24 | 2017-12-28 | Washington State University | Three-dimensional tissue matrix scaffold system |
-
2020
- 2020-12-04 EP EP20816241.2A patent/EP4164706A1/en active Pending
- 2020-12-04 WO PCT/EP2020/084615 patent/WO2021110908A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021110908A1 (en) | 2021-06-10 |
WO2021110908A9 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tavakol et al. | Injectable, scalable 3D tissue-engineered model of marrow hematopoiesis | |
Lih et al. | Biomimetic porous PLGA scaffolds incorporating decellularized extracellular matrix for kidney tissue regeneration | |
Zhang et al. | A PEGylated fibrin patch for mesenchymal stem cell delivery | |
AU2014373966B2 (en) | Tissue grafts and methods of making and using the same | |
WO2011116125A2 (en) | Multilayered vascular tubes | |
KR101628821B1 (en) | Biocompatible Solubilized Scaffold Extract Derived from Decellularized Organ Tissue, Method for Preparating the Biocompatible Scaffold Extract and Uses for Thereof | |
Shen et al. | Construction of ureteral grafts by seeding urothelial cells and bone marrow mesenchymal stem cells into polycaprolactone-lecithin electrospun fibers | |
Nakamura et al. | Induction of in vivo ectopic hematopoiesis by a three-dimensional structured extracellular matrix derived from decellularized cancellous bone | |
CN115305233A (en) | Preparation and application of daidzein and apigenin composite agarose-collagen hydrogel three-dimensional culture stem cells and extracellular vesicles | |
WO2008049281A1 (en) | Construction method of hepatic tissue engineering construct and the hepatic tissue engineering construct | |
Duan et al. | Bioink derived from human placenta supporting angiogenesis | |
JP3421741B2 (en) | Artificial bone marrow, blood cell proliferation method | |
Hashemi et al. | Comparison of the ex vivo expansion of UCB-derived CD34+ in 3D DBM/MBA scaffolds with USSC as a feeder layer | |
EP4164706A1 (en) | Device and process for tissue-engineering and regenerative medicine | |
Nandakumar et al. | Bioengineered 3D microfibrous‐matrix modulates osteopontin release from MSCs and facilitates the expansion of hematopoietic stem cells | |
CN106659560A (en) | Gonad-derived side population stem cells | |
WO2021090945A1 (en) | Cell culture for treating disease of lower extremity | |
Li et al. | Pulmonary decellularized extracellular matrix (dECM) modified polyethylene terephthalate three-dimensional cell carriers regulate the proliferation and paracrine activity of mesenchymal stem cells | |
WO2024090312A1 (en) | Artificial organ and production method for same | |
Kyryk et al. | 3D culture of murine adipose-derived multipotent mesenchymal stromal cells in hydrogel based on carbomer 974P | |
WO2021065989A1 (en) | Method for increasing proportion of cd56+ cells | |
Harff | Toward the Construction of a Vascularized, Hydrogel-Based Lymph Node Model for In Vitro and In Vivo Therapeutic Applications | |
Li et al. | Pancreatic line cell differentiation of bone marrow mesenchymal stromal cells in acellular pancreatic scaffolds | |
Markowicz et al. | Enhancing the vascularization of three-dimensional scaffolds: new strategies in tissue regeneration and tissue engineering | |
Mori et al. | Regenerative cartilage made by fusion of cartilage elements derived from chondrocyte sheets prepared in temperature-responsive culture dishes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220627 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20240327 |